BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, December 13, 2024
See today's BioWorld Asia
Home
» CBMG takes Agreen's T cell immune therapy for $3.28M
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
CBMG takes Agreen's T cell immune therapy for $3.28M
Aug. 13, 2014
By
Shannon Ellis
No Comments
SHANGHAI – Cellular Biomedicine Group Inc., a stem cell and immunotherapy company headquartered in Shanghai, has acquired Beijing Agreen Biotech Co. Ltd. The deal will bring patents, people and the promise of revenue to its new owner.
BioWorld Asia